Control of T(H)17 cells occurs in the small intestine

Article

关键词: GROWTH-FACTOR-BETA;    EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS;    T-CELLS;    TH17 CELLS;    MONOCLONAL-ANTIBODY;    T-H-17 CELLS;    TGF-BETA;    MICE;    DIFFERENTIATION;    INTERLEUKIN-10;   

DOI  :  10.1038/nature10228

来源: SCIE

【 摘 要 】

Interleukin (IL)-17-producing T helper cells (T(H)17) are a recently identified CD4(+) T cell subset distinct from T helper type 1 (T(H)1) and T helper type 2 (T(H)2) cells(1). T(H)17 cells can drive antigen-specific autoimmune diseases and are considered the main population of pathogenic T cells driving experimental autoimmune encephalomyelitis (EAE)(2), the mouse model for multiple sclerosis. The factors that are needed for the generation of T(H)17 cells have been well characterized(3-6). However, where and how the immune system controls T(H)17 cells in vivo remains unclear. Here, by using a model of tolerance induced by CD3-specific antibody, a model of sepsis and influenza A viral infection (H1N1), we show that pro-inflammatory T(H)17 cells can be redirected to and controlled in the small intestine. T(H)17-specific IL-17A secretion induced expression of the chemokine CCL20 in the small intestine, facilitating the migration of these cells specifically to the small intestine via the CCR6/CCL20 axis. Moreover, we found that T(H)17 cells are controlled by two different mechanisms in the small intestine: first, they are eliminated via the intestinal lumen; second, pro-inflammatory T(H)17 cells simultaneously acquire a regulatory phenotype within vitro and in vivo immune-suppressive properties (rT(H)17). These results identify mechanisms limiting T(H)17 cell pathogenicity and implicate the gastrointestinal tract as a site for control of T(H)17 cells.

【 授权许可】

Free